Caris Life Sciences, Inc. $CAI Shares Sold by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas trimmed its stake in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) by 32.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 109,539 shares of the company’s stock after selling 52,774 shares during the period. Oddo BHF Asset Management Sas’ holdings in Caris Life Sciences were worth $1,959,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Hamilton Lane Advisors LLC acquired a new stake in Caris Life Sciences during the 4th quarter worth about $1,584,000. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Caris Life Sciences by 26.5% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 75,330 shares of the company’s stock worth $2,032,000 after acquiring an additional 15,778 shares in the last quarter. Oak Ridge Investments LLC purchased a new position in shares of Caris Life Sciences in the fourth quarter worth approximately $589,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Caris Life Sciences during the fourth quarter valued at approximately $370,000. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Caris Life Sciences in the 4th quarter valued at approximately $150,000.

Insider Activity at Caris Life Sciences

In other Caris Life Sciences news, Director Jon Halbert bought 68,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was bought at an average cost of $14.56 per share, with a total value of $990,080.00. Following the completion of the transaction, the director directly owned 704,598 shares of the company’s stock, valued at approximately $10,258,946.88. The trade was a 10.68% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeff L. Vacirca purchased 31,050 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $16.15 per share, for a total transaction of $501,457.50. Following the purchase, the director owned 49,671 shares in the company, valued at $802,186.65. The trade was a 166.75% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 50.00% of the stock is currently owned by company insiders.

Caris Life Sciences Stock Up 3.2%

Shares of Caris Life Sciences stock opened at $16.09 on Friday. The firm has a market cap of $4.55 billion and a price-to-earnings ratio of -2.11. The company has a debt-to-equity ratio of 0.64, a current ratio of 7.05 and a quick ratio of 6.52. Caris Life Sciences, Inc. has a 52-week low of $14.19 and a 52-week high of $42.50. The stock has a 50-day simple moving average of $16.98 and a 200-day simple moving average of $19.07.

Caris Life Sciences declared that its board has authorized a stock buyback plan on Monday, June 8th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2.1% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

A number of equities analysts recently commented on CAI shares. Wolfe Research lowered shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Piper Sandler assumed coverage on Caris Life Sciences in a report on Friday, April 10th. They issued a “neutral” rating and a $21.00 target price for the company. Wall Street Zen cut Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. New Street Research assumed coverage on Caris Life Sciences in a report on Friday, May 8th. They set a “market perform” rating on the stock. Finally, Evercore set a $25.00 price objective on Caris Life Sciences in a research note on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $26.11.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.